US Patent Issued to In3Bio on March 25 for "Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors" (Belgian, Spanish Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,257,245, issued on March 25, was assigned to In3Bio Ltd. (Hamilton, Bermuda).

"Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors" was invented by Erik D'Hondt (Bazel, Belgium) and Miguel Angel Molina-Vila (Badalona, Spain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining Anaplastic Lymphoma Kinase Inhibitors (ALK Inhibitors) and anti-EGF antibodies for ...